Hadassah

Placental Cells Found to Have Potential to Mitigate Acute Radiation Syndrome

Monday, Oct 24 2011

"In pre-clinical studies," notes Prof. Raphael Gorodetsky, head of the Biotechnology and Radiobiology Laboratory at the Sharrett Institute of Oncology at Hadassah University Medical Center, "we found that placental-derived cells potentially have the ability to increase the survival rate of animals following exposure to lethal doses of total body irradiation."

These placental (PLX) cells, developed by Pluristem Therapeutics Inc., treat life-threatening complications associated with Acute Radiation Syndrome (ARS).

During the studies, animals were injected intravenously with either PLX cells or a placebo, on the day after being exposed to lethal doses of radiation. Nine days following treatment with the PLX cells, the animals' bone marrow and spleen were examined for signs of hematopoietic (blood forming) tissue. On day 23, bone marrow and blood samples were examined in the surviving animals. Overall survival and body weight changes were also monitored. The researchers found in the animals treated with the PLX cells:

  • an up to four-fold increase in the survival rate accompanied by a corresponding weight regain
  • an increase in red-cell count on days 21-23
  • an elevated number of hematopoietic colonies on day 9

Over the next few months, Prof. Gorodetsky and his team will focus on better understanding the PLX cells' mechanism of action as an "off the shelf" post radiation treatment, which could potentially be used in the future for treating ARS patients.

"While our experiments using PLX cells in treating radiation exposure are ongoing and still evolving, these initial data are very encouraging," said Zami Aberman, Chairman and Chief Executive Officer of Pluristem. "PLX cells as a sole treatment may potentially enhance the survival of lethally irradiated individuals. Moreover, since our previous work indicated that PLX cells can enhance the engraftment of hematopoietic stem cells from cord blood, we can offer a multifaceted approach to reduce and treat the destruction of bone marrow that occurs following exposure to high-dose ionizing radiation. Stockpiled PLX cells can be administered acutely and as a bridging therapy to protect the bone marrow."

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Tuesday, Jun 20 2017

Send in the Clowns: A Hadassah UK Dispatch

This week Hadassah UK (HUK) brought in one of the Hadassah Medical Organization's best and more unusual, head medical clown David Barashi (DuSH).

READ MORE ›
alt_text

Friday, Jun 16 2017

Hadassah’s Director General Receives Honorary PhD from Cyprus Medical School

For sharing his knowledge and experience with senior officials in the Cyprus medical system, Prof. Zeev Rotstein, Director General of the Hadassah Medical Organization, was awarded an honorary PhD from the St. George University of London’s Medical Program at the University of Nicosia Medical School in Cyprus.

READ MORE ›
alt_text

Thursday, Jun 8 2017

Hadassah Doctors Discover Bullet
in 12-Year-Old’s Arm

Muhammad Baduan, age 12, had been experiencing pain in his arm on and off for months. Hadassah Hospital Ein Kerem Emergency Room physicians put an end to the boy’s pain when they solved the mystery: Muhammad had a 22-millimeter bullet hidden in that arm--a bullet that had been shot into the air as part of a post-wedding ceremony celebration.

READ MORE ›
alt_text

Monday, Jun 5 2017

Hadassah Cutting-Edge Neuropsychiatrist Keynotes Alzheimer’s Conference

“The key is to give medicines much earlier--before the brain material has been destroyed by Alzheimer’s disease,” Dr. Shahar Arzy, head of the Hadassah Medical Organization’s Computational Neuropsychiatry Laboratory, told his audience at the Alzheimer’s Foundation of America (AFA)’s New York Educational Conference on May 5, 2017.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More